Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct;22(10):807-826.
doi: 10.1038/s41573-023-00772-9. Epub 2023 Aug 31.

Antimalarial drug discovery: progress and approaches

Jair L Siqueira-Neto  1 , Kathryn J Wicht  2   3 , Kelly Chibale  2   3 , Jeremy N Burrows  4 , David A Fidock  5 , Elizabeth A Winzeler  6
Affiliations
Review

Antimalarial drug discovery: progress and approaches

Jair L Siqueira-Neto et al. Nat Rev Drug Discov. 2023 Oct.

Erratum in

Abstract

Recent antimalarial drug discovery has been a race to produce new medicines that overcome emerging drug resistance, whilst considering safety and improving dosing convenience. Discovery efforts have yielded a variety of new molecules, many with novel modes of action, and the most advanced are in late-stage clinical development. These discoveries have led to a deeper understanding of how antimalarial drugs act, the identification of a new generation of drug targets, and multiple structure-based chemistry initiatives. The limited pool of funding means it is vital to prioritize new drug candidates. They should exhibit high potency, a low propensity for resistance, a pharmacokinetic profile that favours infrequent dosing, low cost, preclinical results that demonstrate safety and tolerability in women and infants, and preferably the ability to block Plasmodium transmission to Anopheles mosquito vectors. In this Review, we describe the approaches that have been successful, progress in preclinical and clinical development, and existing challenges. We illustrate how antimalarial drug discovery can serve as a model for drug discovery in diseases of poverty.

PubMed Disclaimer

Conflict of interest statement

Competing interests

J.N.B. is employed by the Medicines for Malaria Venture, which has a stake in developing many of the drugs cited in this Review.

Figures

Fig. 1 |
Fig. 1 |. Malaria therapies in the context of the Plasmodium parasite lifecycle.
During its blood meal on a human host, the female Anopheles species mosquito delivers sporozoites that enter the skin and subsequently target liver cells (hepatocytes). Within the liver, the parasite matures into schizonts (or dormant hypnozoites for Plasmodium vivax and Plasmodium ovale), followed by bursting merozoites that invade erythrocytes (the asexual blood stage). The parasite forms a ring in each erythrocyte that grows into a trophozoite with an acidic digestive vacuole that digests haemoglobin to liberate peptides and amino acids required for protein synthesis. These parasites mature into multinucleated schizonts, from which thousands of merozoites rupture, allowing for rapid replication as they reinvade new red blood cells. Small percentages of merozoites differentiate into male and female gametocytes to initiate the sexual transmission stage, where parasites are ingested by a female mosquito during its blood meal to continue the cycle. Antimalarial drugs that act on the asexual blood stage are categorized as target candidate profile 1 (TCP-1), whereas molecules active against liver-stage hypnozoites (P. vivax) or hepatic schizonts are in categories TCP-3 and TCP-4, respectively. Drugs that block transmission to the mosquito by inhibiting gametocytes are TCP-5 compounds, and those that block transmission by targeting the insect vector are TCP-6 (endectocides). Two or more compounds are combined into clinical therapies with target product profile 1 (TPP-1) and TPP-2 (ref. 240). TPP-1 focuses on drugs for chemotherapeutic treatment of acute uncomplicated malaria in children or adults, using compounds with TCP-1; if possible, TCP-3, TCP-4 and TCP-5 compounds are added to reduce relapse, provide post-treatment prophylaxis and block transmission. TPP-2 focuses on prevention, in high-transmission areas or during epidemics, and gives protection via TCP-1 and, ideally, TCP-4 for prophylaxis and TCP-5 to clear gametocytaemia in asymptomatic individuals. Antimalarials approved for clinical use are listed for each TCP category.
Fig. 2 |
Fig. 2 |. Antimalarial drug discovery and development pipeline.
Drug candidates in preclinical exploratory phase, human volunteer phase and patient exploratory phase as well as approved drugs are listed. They are grouped in rows according to their target candidate profile (TCP), which represents the stage of disease being targeted. Monoclonal antibodies MAM01 (ATRC-501), L9LS and CIS43LS block hepatocyte infection from sporozoites. Ruxolitinib is an immunomodulator and is being tested in combination with antimalarial therapy to modulate the long-term host immune response.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Carter R & Mendis KN Evolutionary and historical aspects of the burden of malaria. Clin. Microbiol. Rev 15, 564–594 (2002). - PMC - PubMed
    1. Ashley EA, Pyae Phyo A & Woodrow CJ Malaria. Lancet 391, 1608–1621 (2018). - PubMed
    1. Lal AA, Rajvanshi H, Jayswar H, Das A & Bharti PK Malaria elimination: using past and present experience to make malaria-free India by 2030. J. Vector Borne Dis 56, 60–65 (2019). - PubMed
    1. World Health Organization. World Malaria Report https://www.who.int/teams/global-malaria-programme/reports/world-malaria... (2022).
    1. Chandramohan D et al. Seasonal malaria vaccination with or without seasonal malaria chemoprevention. N. Engl. J. Med 385, 1005–1017 (2021). - PubMed

Publication types